Tufan Egeli

Dr. Tufan Egeli

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2021 in Endocrine Pathology
Verified
Journal Article
Closed access
AAAnil Aysal
Anil Aysal
CACihan Aǧalar
Cihan Aǧalar
TETufan Egeli
Tufan Egeli
TUTARKAN UNEK
TARKAN UNEK
IOIlhan Oztop
Ilhan Oztop
OSOzgul Sagol
Ozgul Sagol

1 June 2012 in Balkan Medical Journal
Verified
Journal Article
Closed access
TETufan Egeli
Tufan Egeli
ASAli Ibrahim Sevinc
Ali Ibrahim Sevinc
SBSeymen Bora
Seymen Bora
MYMehmet Can Yakut
Mehmet Can Yakut
TCTansu Cevizci
Tansu Cevizci
ASAli Riza Sisman
Ali Riza Sisman
Seroma is the most common complication after breast surgery. Several methods have been proposed to prevent seroma, but none of these provided a significant effect. A prolonged wound healing process is the most important cause of seroma. Microporous polysaccharide hemospheres (MPH) are used to achieve hemostasis. They may also accelerate wound healing. In this study, the effects of MPH on seroma formation were investigated. Female Wistar rats weighing between 200 g and 250 g were used. There were eight rats in each of the control and study groups. Right breast mastectomy and axillary dissection were performed in all rats. While no application was performed after the operation in the control group, MPH was locally applied to the surgical site in the study group. Ten days after the operation, seroma fluid was aspirated and the total volume was recorded. The aspirates were analyzed and tissue samples were obtained from the surgical site. Seroma was significantly lower in the study group (p=0.001). The mean albumin and lactate dehydrogenase levels were significantly lower in the study group (p=0.003). Pathological examination revealed that increase in fibrous tissue was significantly greater in the control group (p=0.032). MPH may reduce seroma after mastectomy.

1 June 2023 in Experimental and Clinical Transplantation
Verified
Journal Article
Closed access
IAIbrahim Astarcıoglu
Ibrahim Astarcıoglu
TETufan Egeli
Tufan Egeli
AGAytac Gulcu
Aytac Gulcu
MOMucahit Ozbilgin
Mucahit Ozbilgin
CACihan Agalar
Cihan Agalar
TUTarkan Unek
Tarkan Unek
Vascular complications after liver trans-plant can be lethal. High levels of suspicion and aggressive use of diagnostic tools may help with early diagnosis and treatment. Here, we share our experiences regarding this topic. Adult and pediatric patients who had liver transplant between February 1997 and June 2018 in our clinic were included in the study. Patients were grouped according to age (pediatric patients were those under 18 years old), male versus female, indication for transplant, type of liver transplant, type of vascular complication, treatment, and survival after treatment. We analyzed the statistical incidence of vascular complications according to age, male versus female, and type of liver transplant. Our analyses included 607 liver transplant procedures, including 7 retransplants, with 349 (57.4%) from living donors and 258 (42.6%) from deceased donors. Of total patients, 539 were adults (89.8%) and 61 were children (10.2%). Vascular complications occurred in 25 patients (4.1%), with hepatic artery complications seen in 13 patients (2.1%) (10 adults [1.8%] and 3 children [4.9%]), portal vein com-plications seen in 9 patients (1.5%) (6 adults [1.1%] and 3 children [4.9%]), and hepatic vein complications seen in 3 patients (0.5%) (2 adults [0.36%] and 1 child [1.6%]). Rate of vascular complications was statistically higher in pediatric patients (11.4% vs 3.3%; P = .007) and higher but not statistically in recipients of livers from living donors (5.2% vs 2.7%; P = .19). Twelve patients (48.8%) were treated with endovascular approach, and 11 (0.44%) required surgical treatment. Two patients underwent immediate retransplant due to hepatic artery thrombosis. Because vascular complications are the most severe complications after liver transplant, there must be close follow-up of vascular anastomoses, particularly early postoperatively, with radiologic methods. In cases of vascular complications, emergent treatment, including endovascular interventions, surgery, and retransplant, must be performed.

1 February 2019 in Experimental and Clinical Transplantation
Verified
Journal Article
Closed access
TETufan Egeli
Tufan Egeli
TUTarkan Unek
Tarkan Unek
MOMucahit Ozbilgin
Mucahit Ozbilgin
CACihan Agalar
Cihan Agalar
SDSerhan Derici
Serhan Derici
IAIbrahim Astarcioglu
Ibrahim Astarcioglu
Our objective was to analyze characteristics, risk factors, and incidence of de novo malignancies after liver transplant. The hospital records of 557 patients who underwent liver transplant were analyzed from the point of de novo malignancy development. We evaluated the demographic features and survival of these patients retrospectively. The research covered 429 patients, 9 (2%) of whom developed de novo malignancy. All of these patients were male (100%), and their mean (SD) age was 51.33 (4.69) years (range, 45-65 y). Indications for transplant included alcohol related in 4 cases, chronic hepatitis B in 2 cases, chronic hepatitis B and C in 1 case, chronic hepatitis B and D in 1 case, and chronic hepatitis C and alcohol-related cirrhosis in 1 case. The mean (SD) time from transplant to cancer diagnosis was 63.41 (37.10) months (range, 17-122 mo). The types of tumors were lung cancer, lymphoma, neuroendocrine tumor of lung, nasopharyngeal cancer, and squamous cell carcinoma of the skin. Seven cases received chemotherapy with or without radiotherapy. Two cases received surgery and radiotherapy. One patient underwent surgical treatment. One patient died before treatment was started. In recent years, improvements in surgical techniques and immunosuppressive therapies have helped prolong survival of patients who undergo liver transplant. However, this also has led to a rise in the incidence of long-term complications such as de novo malignancy. These patients are more likely to develop de novo malignancy than the general population, for which chronic immunosuppression is identified as a major risk factor. Early diagnosis and treatment of de novo malignancies can help obtain better prognosis and higher survival rates in these patients.

21 November 2014 in Wiener klinische Wochenschrift
Verified
Journal Article
Closed access
PDF file
CACanan Altay
Canan Altay
EYEsra Yavuz
Esra Yavuz
TETufan Egeli
Tufan Egeli
ACAras Emre Canda
Aras Emre Canda
SSSulen Sarioglu
Sulen Sarioglu
MSMustafa Secil
Mustafa Secil

30 August 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Closed access
TYTuğba YANIK YALÇIN
Tuğba YANIK YALÇIN
ÖAÖzlem Azap
Özlem Azap
Adem KoseAdem Kose
Adem Kose
YBYasar Bayindir
Yasar Bayindir
ESElif Mukime Saricaoglu
Elif Mukime Saricaoglu
MHMehmet Haberal
Mehmet Haberal
Background/aim: The aim of this study is to evaluate the distribution, sources, clinical features, and mortality rates of bacteremia due to evaluation of extensively drug-resistant (XDR) gram negative among solid-organ transplant (SOT) recipients. Materials and methods: A retrospective study of SOT recipients with bacteremia due to XDR gram-negative pathogens in 11 centers between 2016 and 2018 was conducted. Patients' records were evaluated. Results: Of 171 bacteremia that occurred in 164 SOT recipients, 93 (56.7%) were liver, 46 (28%) kidney, 14 (8.5%) heart, and 11 (6.7%) lung recipients. Bacteremia episodes were recorded in the first year in 63.7% of the patients (n = 109), early-onset bacteremia was recorded in 45% (n = 77) of the episodes. In multivariate analysis, catheter-associated bacteremia was an independent risk factor for 7-day mortality (p = 0.037), and early-onset bacteremia was found as an independent risk factor for 30-day mortality (p = 0.017). Conclusion: Difficult-to-treat infections due to XDR bacteria in SOT recipients shadow the success of transplantation. Central venous catheters seem to be the main risk factor. Judicious use of medical devices is of pivotal importance.